The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Aracytine     4-amino-1-[(2R,3S,4S,5R)-3,4- dihydroxy-5...

Synonyms: Cytonal, Cytosar, cytarabine, Aracytidine, Cytosar-U, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of cytarabine


Psychiatry related information on cytarabine


High impact information on cytarabine


Chemical compound and disease context of cytarabine


Biological context of cytarabine


Anatomical context of cytarabine


Associations of cytarabine with other chemical compounds


Gene context of cytarabine


Analytical, diagnostic and therapeutic context of cytarabine


  1. Transcriptional regulation of c-jun gene expression by arabinofuranosylcytosine in human myeloid leukemia cells. Kharbanda, S.M., Sherman, M.L., Kufe, D.W. J. Clin. Invest. (1990) [Pubmed]
  2. Cellular quantitation of in vivo effects of 1-beta-D-arabinofuranosylcytosine on leukemia L1210. Edelstein, M., Valeriote, F., Vietti, T. J. Natl. Cancer Inst. (1977) [Pubmed]
  3. Repression and activation of the genome of herpes simplex viruses in human cells. Wigdahl, B.L., Isom, H.C., Rapp, F. Proc. Natl. Acad. Sci. U.S.A. (1981) [Pubmed]
  4. Enhanced metabolism of 1-beta-D-arabinofuranosylcytosine in Down syndrome cells: a contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukemia. Taub, J.W., Matherly, L.H., Stout, M.L., Buck, S.A., Gurney, J.G., Ravindranath, Y. Blood (1996) [Pubmed]
  5. Synthesis of adult-type hemoglobin in human erythremia cell line. Kaku, M., Yagawa, K., Nakamura, K., Okano, H. Blood (1984) [Pubmed]
  6. Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Jabbour, E., O'Brien, S., Kantarjian, H., Garcia-Manero, G., Ferrajoli, A., Ravandi, F., Cabanillas, M., Thomas, D.A. Blood (2007) [Pubmed]
  7. An inhibitor of DNA recombination blocks memory consolidation, but not reconsolidation, in context fear conditioning. Colón-Cesario, M., Wang, J., Ramos, X., García, H.G., Dávila, J.J., Laguna, J., Rosado, C., Peña de Ortiz, S. J. Neurosci. (2006) [Pubmed]
  8. Cellular differentiation, cytidine analogs and DNA methylation. Jones, P.A., Taylor, S.M. Cell (1980) [Pubmed]
  9. Induction of terminal differentiation in human K562 erythroleukemia cells by arabinofuranosylcytosine. Luisi-DeLuca, C., Mitchell, T., Spriggs, D., Kufe, D.W. J. Clin. Invest. (1984) [Pubmed]
  10. 1-beta-D-arabinofuranosylcytosine-induced chromatid breakage: effect of inhibition of DNA synthesis. Benedict, W.F., Rucker, N., Karon, M. J. Natl. Cancer Inst. (1975) [Pubmed]
  11. Transcription of the human hsp70 gene is induced by serum stimulation. Wu, B.J., Morimoto, R.I. Proc. Natl. Acad. Sci. U.S.A. (1985) [Pubmed]
  12. Schedule optimization of hydroxyurea and 1-beta-D-arabinofuranosylcytosine in sarcoma 180 in vitro. Shackney, S.E., Ford, S.S., Occhipinti, S.J., Ritch, P.S., Riccardi, R., Erickson, B.W. Cancer Res. (1982) [Pubmed]
  13. Cellular phosphorylation of 1-beta-D-arabinofuranosylcytosine 5-azacytidine with intact fibrosarcoma and leukemic cells. Lee, T., Karon, M., Monparler, R.L. Cancer Res. (1975) [Pubmed]
  14. Histidinol-mediated improvement in the specificity of 1-beta-D-arabinofuranosylcytosine and 5-fluorouracil in L 1210 leukemia-bearing mice. Warrington, R.C., Muzyka, T.G., Fang, W.D. Cancer Res. (1984) [Pubmed]
  15. Simultaneous treatment with 1-beta-D-arabinofuranosylcytosine and daunorubicin induces cross-resistance to both drugs due to a combination-specific mechanism in HL60 cells. Takemura, H., Urasaki, Y., Yoshida, A., Fukushima, T., Ueda, T. Cancer Res. (2001) [Pubmed]
  16. Thymidine as a kinetic and biochemical modulator of 1-beta-D-arabinofuranosylcytosine in human acute nonlymphocytic leukemia. Blumenreich, M.S., Chou, T.C., Andreeff, M., Vale, K., Clarkson, B.D., Young, C.W. Cancer Res. (1984) [Pubmed]
  17. Flow cytometric measurement of total DNA content and incorporated bromodeoxyuridine. Dolbeare, F., Gratzner, H., Pallavicini, M.G., Gray, J.W. Proc. Natl. Acad. Sci. U.S.A. (1983) [Pubmed]
  18. Activation of the CPP32 protease in apoptosis induced by 1-beta-D-arabinofuranosylcytosine and other DNA-damaging agents. Datta, R., Banach, D., Kojima, H., Talanian, R.V., Alnemri, E.S., Wong, W.W., Kufe, D.W. Blood (1996) [Pubmed]
  19. Activation of protein kinase Cdelta in human myeloid leukemia cells treated with 1-beta-D-arabinofuranosylcytosine. Emoto, Y., Kisaki, H., Manome, Y., Kharbanda, S., Kufe, D. Blood (1996) [Pubmed]
  20. Capacity of individual chronic lymphatic leukemia lymphocytes and leukemic blast cells for repair of O6-ethylguanine in DNA: relation to chemosensitivity in vitro and treatment outcome. Müller, M.R., Seiler, F., Thomale, J., Buschfort, C., Rajewsky, M.F., Seeber, S. Cancer Res. (1994) [Pubmed]
  21. A critical role for uridine nucleotides in the regulation of deoxycytidine kinase and the concentration dependence of 1-beta-D-arabinofuranosylcytosine phosphorylation in human leukemia cells. White, J.C., Capizzi, R.L. Cancer Res. (1991) [Pubmed]
  22. Synergistic interaction between 1-beta-D-arabinofuranosylcytosine, thymidine, and hydroxyurea against human B cells and leukemic blasts in vitro. Streifel, J.A., Howell, S.B. Proc. Natl. Acad. Sci. U.S.A. (1981) [Pubmed]
  23. Isolation and culture of motoneurons from embryonic chicken spinal cords. Masuko, S., Kuromi, H., Shimada, Y. Proc. Natl. Acad. Sci. U.S.A. (1979) [Pubmed]
  24. Differential nuclear protein binding to 5-azacytosine-containing DNA as a potential mechanism for 5-aza-2'-deoxycytidine resistance. Michalowsky, L.A., Jones, P.A. Mol. Cell. Biol. (1987) [Pubmed]
  25. Differential effect of N-(phosphonacetyl)-L-aspartate on 1-beta-D-arabinofuranosylcytosine metabolism and cytotoxicity in human leukemia and normal bone marrow progenitors. Grant, S., Rauscher, F., Cadman, E. Cancer Res. (1982) [Pubmed]
  26. Polyamine biosynthesis is required for the maintenance of peripheral blood cell elements in the rat. Luk, G.D., Sharkis, S.J., Abeloff, M.D., McCann, P.P., Sjoerdsma, A., Baylin, S.B. Proc. Natl. Acad. Sci. U.S.A. (1983) [Pubmed]
  27. Activation of an imprinted Igf 2 gene in mouse somatic cell cultures. Eversole-Cire, P., Ferguson-Smith, A.C., Sasaki, H., Brown, K.D., Cattanach, B.M., Gonzales, F.A., Surani, M.A., Jones, P.A. Mol. Cell. Biol. (1993) [Pubmed]
  28. Clinical pharmacology of 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate, an orally administered long-acting derivative of low-dose 1-beta-D-arabinofuranosylcytosine. Ueda, T., Kamiya, K., Urasaki, Y., Wataya, S., Kawai, Y., Tsutani, H., Sugiyama, M., Nakamura, T. Cancer Res. (1994) [Pubmed]
  29. Adriamycin-induced delayed erythropoietic injury expressed following anemia stress. Braunschweiger, P.G., Schenken, L.L., Schiffer, L.M. Cancer Res. (1980) [Pubmed]
  30. Kinetics and mechanism of the 1-beta-D-arabinofuranosylcytosine-induced potentiation of cis-diamminedichloroplatinum(II) cytotoxicity. Vadi, H., Drewinko, B. Cancer Res. (1986) [Pubmed]
  31. Effects of selective checkpoint kinase 1 inhibition on cytarabine cytotoxicity in acute myelogenous leukemia cells in vitro. Schenk, E.L., Koh, B.D., Flatten, K.S., Peterson, K.L., Parry, D., Hess, A.D., Smith, B.D., Karp, J.E., Karnitz, L.M., Kaufmann, S.H. Clin. Cancer Res. (2012) [Pubmed]
  32. An MCL1-overexpressing Burkitt lymphoma subline exhibits enhanced survival on exposure to serum deprivation, topoisomerase inhibitors, or staurosporine but remains sensitive to 1-beta-D-arabinofuranosylcytosine. Vrana, J.A., Bieszczad, C.K., Cleaveland, E.S., Ma, Y., Park, J.P., Mohandas, T.K., Craig, R.W. Cancer Res. (2002) [Pubmed]
  33. Activation of SAPK/JNK signaling by protein kinase Cdelta in response to DNA damage. Yoshida, K., Miki, Y., Kufe, D. J. Biol. Chem. (2002) [Pubmed]
  34. The MUC1 oncoprotein activates the anti-apoptotic phosphoinositide 3-kinase/Akt and Bcl-xL pathways in rat 3Y1 fibroblasts. Raina, D., Kharbanda, S., Kufe, D. J. Biol. Chem. (2004) [Pubmed]
  35. Distinct functions for WRN and TP53 in a shared pathway of cellular response to 1-beta-D-arabinofuranosylcytosine and bleomycin. Poot, M., Jin, X., Hill, J.P., Gollahon, K.A., Rabinovitch, P.S. Exp. Cell Res. (2004) [Pubmed]
  36. Evidence for involvement of mitogen-activated protein kinase, rather than stress-activated protein kinase, in potentiation of 1-beta-D-arabinofuranosylcytosine-induced apoptosis by interruption of protein kinase C signaling. Jarvis, W.D., Fornari, F.A., Tombes, R.M., Erukulla, R.K., Bittman, R., Schwartz, G.K., Dent, P., Grant, S. Mol. Pharmacol. (1998) [Pubmed]
  37. Clinical correlations of leukemic clonogenic cell chemosensitivity assessed by in vitro continuous exposure to drugs. Park, C.H., Wiernik, P.H., Morrison, F.S., Amare, M., Van Sloten, K.V., Maloney, T.R. Cancer Res. (1983) [Pubmed]
  38. Pharmacokinetics of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in leukemic cells after intravenous and subcutaneous administration of 1-beta-D-arabinofuranosylcytosine. Liliemark, J.O., Paul, C.Y., Gahrton, C.G., Peterson, C.O. Cancer Res. (1985) [Pubmed]
  39. Therapeutic activity of a thioether-lipid conjugate of 1-beta-D-arabinofuranosylcytosine in human colorectal cancer xenografts. Herrmann, R., Berdel, W.E. Cancer Res. (1992) [Pubmed]
WikiGenes - Universities